Last reviewed · How we verify
NCT03252665
Efficacy of Intracoronary Infusion of Different Medicine in STEMI Patients Undergoing Primary PCI
Phase 4 trial testing Alprostadil in ST Segment Elevation Myocardial Infarction in 600 participants. Status unknown.
30 June 2019
Quick facts
| Lead sponsor | RenJi Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 600 |
| Start date | 1 September 2017 |
| Primary completion | 30 June 2019 |
| Estimated completion | 30 June 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- Alprostadil (ALPROSTADIL) — full drug profile →
- Nicorandil — full drug profile →
- Nitroglycerin (glyceryl trinitrate) — full drug profile →
Conditions studied
- ST Segment Elevation Myocardial Infarction — all drugs for ST Segment Elevation Myocardial Infarction →
Sponsor
RenJi Hospital
Who can join
Adults 18 to 75, any sex, with ST Segment Elevation Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study intends to evaluate the efficacy of different medicine delivering by targed perfusion catheter incoronary administration on epicardial, myocardial perfusion and clinical outcomes in STEMI patients undergoing primary PCI.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Myocardial protective effect of intracoronary administration of nicorandil and alprostadil via targeted perfusion microcatheter in patients undergoing elective percutaneous coronary intervention: A randomized controlled trial.
Zhang W, Dai J, Zheng X, Xu K, et al · · 2021 · cited 5× · PMID 33847683 · DOI 10.1097/md.0000000000025551 -
The effect of nicorandil compared to placebo on cardiac outcomes of patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention: a meta-analysis.
Gu M, Xu T. · · 2025 · PMID 40182095 · DOI 10.5114/aic.2025.148175
Verify or expand the search:
- PubMed search for NCT03252665
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Alprostadil
Trials testing the same drug.
- NCT03252626 — Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic Stroke · Phase 4 · unknown
- NCT04312555 — Alprostadil as an Adjuvant Therapy With Indirect Angiosomal Revascularization in Critical Limb Ischemia. · Phase 4 · unknown
- NCT03892447 — The Comparative Effectiveness of Alprostadil,Sodium Ferulate and Dopamine in Pediatric Acute Kidney Injury · Phase 4 · unknown
- NCT03027219 — Blood Flow Change After Free Flap Surgery in Diabetic Patients · completed
- NCT03296670 — Efficacy of Intracoronary Infusion of Different Medicine in STEMI Patients With CSFP · Phase 4 · completed
Other recruiting trials for ST Segment Elevation Myocardial Infarction
Currently open trials in the same condition.
- NCT03787745 — Ischemic Postconditioning in STEMI Patients Treated With Primary PCI · NA · recruiting
Other RenJi Hospital trials
Trials by the same sponsor.
- NCT07584733 — Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper · Phase 2 · not yet recruiting
- NCT07537725 — EEG-TMS for Postoperative Delirium After Cardiac Surgery · NA · not yet recruiting
- NCT07527936 — A Study of BEN301 Injection in theTreatment of Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
- NCT07343076 — Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE · NA · not yet recruiting
- NCT07449793 — Biochemical Response and Clinical Outcomes in Patients With PBC · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03252665 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by RenJi Hospital
- Last refreshed: 17 August 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03252665.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing